SCM
FDMT icon

Soleus Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Soleus Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-108,598
Closed -$2.28M – 92
2024
Q2 		$2.28M Sell
108,598
-88,500
-45% -$2.22M 0.2% 77
2024
Q1 		$6.28M Buy
197,098
+151,350
+331% +$3.86M 0.47% 60
2023
Q4 		$927K Sell
45,748
-78,000
-63% -$1.03M 0.1% 63
2023
Q3 		$1.58M Sell
123,748
-95,400
-44% -$1.6M 0.15% 73
2023
Q2 		$3.96M Sell
219,148
-250,252
-53% -$4.61M 0.44% 56
2023
Q1 		$8.07M Buy
469,400
+214,700
+84% +$4.17M 0.84% 34
2022
Q4 		$5.66M Buy
+254,700
New +$3.93M 0.81% 35
2021
Q4 		– Sell
-120,900
Closed -$3.26M – 80
2021
Q3 		$3.26M Buy
120,900
+20,100
+20% +$573K 0.51% 48
2021
Q2 		$2.43M Buy
100,800
+14,700
+17% +$450K 0.37% 47
2021
Q1 		$3.73M Buy
+86,100
New +$3.81M 0.67% 28

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Soleus Capital Management's FDMT Position: Q3 2024 in Review

Soleus Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q3 2024, closing a stake of 108,598 shares — an estimated $2.28M sold.

Soleus Capital Management first reported a position in FDMT in Q1 2021 and held it in 10 quarters. The position peaked at $8.07M in Q1 2023. 140 funds tracked by Wall St. Rank hold FDMT as of Q3 2024.

  • Soleus Capital Management reported no remaining 4D Molecular Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Soleus Capital Management sold 108,598 4D Molecular Therapeutics shares in Q3 2024, an estimated $2.28M.
  • Soleus Capital Management first reported a position in 4D Molecular Therapeutics in Q1 2021 and held it in 10 quarters.
  • Soleus Capital Management's 4D Molecular Therapeutics position peaked at $8.07M in Q1 2023.
  • 140 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2024.

Based on Soleus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.